6,161 results on '"Carbidopa"'
Search Results
2. Sustained Release Oral Formulation for Treatment of Parkinson's Disease
3. A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
4. Carbidopa-Levodopa in Dry AMD With Geographic Atrophy
5. Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa (ADD201)
6. Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease
7. Enhancement of Stroke Rehabilitation With Levodopa (ESTREL)
8. Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients (LDCD-001)
9. The Role of Brain Dopamine in Chronic Pain
10. Neurobiological Drivers of Mobility Resilience: The Dopaminergic System (RES)
11. Gait Analysis in Neurological Disease
12. Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm (RES)
13. Novel Non-opioid Post-surgical Pain Treatment in Females
14. Dopaminergic Dysfunction in Late-Life Depression (D3)
15. A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
16. Montelukast in Parkinson Disease
17. Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia (FMS201)
18. INfusion VErsus STimulation in Parkinson's Disease (INVEST)
19. Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease (SmIle)
20. Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease
21. DTA (Dopaminergic Therapy for Anhedonia) Study
22. A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects
23. A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612 (ND0612/003)
24. Dopaminergic Therapy for Anhedonia - 2 (DTA-2)
25. Subcutaneous Levodopa: A New Engine for the Vintage Molecule.
26. The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson's Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years On.
27. Improved Outcomes When Home-Dose Carbidopa-Levodopa Is Continued in the Geriatric Emergency Department in Patients With Parkinson’s Disease.
28. Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects
29. Personalized Real-Time DBS and PD Mechanisms
30. A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
31. Vigor and the LDR in Parkinson Disease
32. Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES (STIMO-PHARMA)
33. A voltammetric method coupled with chemometrics for determination of a ternary antiparkinson mixture in its dosage form: greenness assessment
34. Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion.
35. Simultaneous sensing of carbidopa and levodopa by a novel strategy based on dual‐emission ratiometric assay of modified carbon dots.
36. A voltammetric method coupled with chemometrics for determination of a ternary antiparkinson mixture in its dosage form: greenness assessment.
37. [3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain.
38. The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications.
39. IGFBP5 Promotes Neuronal Apoptosis in a 6-OHDA-Toxicant Model of Parkinson's Disease by Inhibiting the Sonic Hedgehog Signaling Pathway.
40. Poly(acrylic acid)/Poly(vinyl alcohol) Microarray Patches for Continuous Transdermal Delivery of Levodopa and Carbidopa: In Vitro and In Vivo Studies.
41. Efficient Detection of Droxidopa in the Presence of Carbidopa Using a Modified Screen-Printed Graphite Electrode.
42. Role of Inflammation in the Development of COVID-19 to Parkinson's Disease.
43. Reduced Plasma Levodopa Fluctuations with More Frequent Administration of a Novel Carbidopa/Levodopa Functionally Scored Tablet.
44. Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC‐HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.
45. Diagnostic and therapeutic potential of tonic gamma‐aminobutyric acid from reactive astrocytes in brain diseases.
46. Computer-aided optimization of carbidopa/levodopa orally disintegrating tablets.
47. [18F]F-DOPA Imaging in Patients With Autonomic Failure
48. Pentoxifylline and Parkinsonism
49. Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) (AM IMPAKT)
50. Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation (MOTIVADE)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.